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Mature vasculature contains an endothelial cell lining with a surrounding sheath of pericytes/vascular smooth muscle cells
(VSMCs). Tumor vessels are immature and lack a pericyte sheath. Colocalization of vascular endothelial growth factor receptor
2 (VEGFR-2) and platelet-derived growth factor receptor beta (PDGF-Rβ) reduces pericyte ensheathment of tumor vessels. We
found that a 30% dietary restriction (DR) enhanced vessel maturation in the mouse CT-2A astrocytoma. DR reduced microvessel
densityandVEGFexpressionintheastrocytoma,whileincreasingrecruitmentofpericytes,positiveforalpha-smoothmuscleactin
(α-SMA). Moreover, DR reduced colocalization of VEGF-R2 and PDGF-Rβ, but did not reduce total PDGF-Rβ expression. These
ﬁndings suggest that DR promoted vessel normalization by preventing VEGF-induced inhibition of the PDGF signaling axis in
pericytes. DR appears to shift the tumor vasculature from a leaky immature state to a more mature state. We suggest that vessel
normalization could improve delivery of therapeutic drugs to brain tumors.
1.Introduction
Tumor vascularization, vital to neoplastic progression, pro-
vides nutrients and oxygen to the tumor [1–3]. Proliferation
of vessel-forming endothelial cells is a limiting factor for
tumor growth [4–7]. Accordingly, targeting tumor vessel
proliferation decreases blood ﬂow and nutrient availability,
thus slowing tumor growth [8]. Tumors induce the prolifer-
ative vascular response of host blood vessels by inﬂuencing
the local balance of angiogenic regulators, a rate-limiting
step termed the angiogenic switch [9, 10]. The uncontrolled
production of angiogenic stimulators and the absence of
inhibitors favor vessel growth [10–12].
Normal tissue vasculature contains an endothelial lining
with a surrounding sheath of pericytes/vascular smooth
muscle cells (VSMCs) [13]. In contrast to healthy vessels,
tumorvesselsareimmature,oftenmal-shaped,irregular,and
have a tortuous structure with a leaky endothelial cell lining
[13, 14]. The process of blood vessel maturation involves
ensheathment of neovascular sprouts by α-smooth-muscle-
actin- (α-SMA-) positive pericytes [15]. Pericytes contact
endothelial cells and play an active role in endothelial cell
function and blood ﬂow regulation [15–17]. Mature vessels
contain a variety of contractile proteins including α-SMA,
which is often used as a pericyte marker [15, 18, 19].
The instability of tumor blood vessels is associated with
the absence of a smooth muscle cell sheath [11]. Abnor-
malities in tumor vessel shape and structure not only impair
drug delivery, but also can facilitate metastatic spread [20,
21]. While it may seem that an increase in blood vessel quan-
titywouldprovidesuﬃcientoxygentotumors,theabnormal
vessels deliver less oxygen leading to a hypoxic tumor envi-
ronment [13]. This will further stimulate tumor growth and
aberrant angiogenesis [22, 23]. Vascular endothelial growth
factor (VEGF) and platelet-derived growth factor (PDGF)
signalingdrivesangiogenesisandrecruitmentofperivascular
cells to surround the newly formed blood vessels [24]. VEGF
stimulates endothelial cell migration, proliferation, survival,
permeability, and lumen formation and has become a prime
target of antiangiogenic therapy [13]. Blockage of VEGF
signaling induces vessel normalization and inhibition of new
vessel growth (16). In addition to the pruning of immature
blood vessels, inhibition of VEGF expression also increases
pericyte cell coverage and vessel maturation [25, 26].2 Journal of Oncology
Platelet-derived growth factor (PDGF) coordinates per-
icyte coverage of vascular sprouts through PDGF-Rβ on
vascular smooth muscle cells [27]. Greenberg et al. showed
that, in addition to stimulating endothelial cell proliferation,
VEGF also inhibits neovascularization via its capacity to dis-
rupt vascular smooth muscle cell function [24]. Speciﬁcally,
VEGF prevents pericyte coverage of nascent vascular sprouts
leading to vessel destabilization. VEGF activation of VEGF-
R2 suppresses PDGF-Rβ signaling in VSMCs through the
assembly of a complex consisting of the two receptors. Inhi-
bition of VEGF-R2 prevents the formation of this receptor
complex and restores tissue angiogenesis. Moreover, genetic
deletion of tumor cell VEGF also disrupts the receptor
complex and consequently increases tumor vessel mat-
uration. These ﬁndings are important as they reveal a di-
chotomous role for VEGF signaling as a promoter of en-
dothelial cell function and as an inhibitor of VSMCs and
vessel maturation [24, 26, 28, 29].
VEGF expression is greater in tumor cells than in normal
cells [30–33]. Reduced VEGF expression reduces angiogene-
sis while increasing vessel maturation [24]. Mukherjee et al.
demonstrated that a 30% dietary restriction (DR) inhibits
angiogenesis and reduces prostate tumor growth [34]. We
showed that DR in mice reduces microvessel density in
experimental mouse and human brain tumors [35, 36].
Powolny et al. demonstrated that DR attenuates tumor
growth and reduces vascular density. They also found that a
40% DR signiﬁcantly reduced VEGF gene and protein ex-
pression in rat prostate tumors [37]. These studies show
that DR is a potentially viable nontoxic therapeutic approach
for managing malignant brain tumor growth, for reducing
tumor angiogenesis, and for increasing long-term survival in
mice bearing orthotopically implanted tumors [35–38].
DR is produced by restricting the total caloric content
administered to subjects. However, a distinction from star-
vation is that DR does not cause anorexia or malnutrition
[34, 39–42]. It is important to note that the total reduction
of calories, rather than the macronutritional content of the
food, proves most important to producing the eﬀects of
reducingtumorgrowthandinlimitingangiogenesis[34,39].
Although prior studies showed that dietary restriction is
antiangiogenic when initiated early in tumor development,
no prior studies have identiﬁed the mechanisms by which
dietary restriction is eﬀective in correcting vasculature.
In this paper, we show that DR enhances vessel mat-
uration and stabilization in the highly vascularized CT-2A
mouse astrocytoma. In addition to reducing VEGF expres-
sion, we also found that DR decreased colocalization of
VEGF-R2 with PDGF-Rβ. Our ﬁndings suggest that DR
imparts its antiangiogenic and vessel maturating eﬀects on
the CT-2A tumor via the reduction of VEGF expression
promoting VSMC ensheathment of vascular sprouts.
2.MaterialsandMethods
2.1. Mice. Mice of the C57BL/6J strain were obtained from
the Jackson laboratory (Bar Harbor, ME, USA). The mice
were propagated in the animal care facility of the Biology
Department of Boston College, using animal husbandry
conditionsdescribedpreviously[43].Malemice(8–10weeks
of age) were used for the studies and were provided with
food either ad libitum (AL) or under restricted conditions
(as described below). Water was provided ad libitum to all
mice. The animal room was maintained at 22◦C, and cotton
nesting pads were provided for additional warmth. All
animal experiments were carried out with ethical committee
approvalinaccordancewiththeNational Institutes ofHealth
Guide for the Care and Use of Laboratory Animals and were
approved by the Institutional Care Committee.
2.2. Brain Tumor Model. The syngeneic CT-2A experimental
mouse brain tumor was generated in our laboratory after
implantation of 20-methylcholanthrene into the cerebral
cortex of a C57BL/6 mouse according to the procedure of
Zimmerman [45, 46]. Histologically, the CT-2A brain
tumor is broadly classiﬁed as a poorly diﬀerentiated highly
malignant anaplastic astrocytoma [46]. The tumor grows
orthotopically as a soft, noncohesive, and highly vascularised
mass.
2.3. Intracerebral Tumor Implantation. The CT-2A tumor
was implanted into the cerebral cortex of C57BL/6J mice
using a trocar as we previously described [47, 48]. Brieﬂy,
mice were anaesthetized with pentobarbital (Vet Labs, Inc)
intraperitoneally and their heads were shaved and swabbed
with 70% ethyl alcohol under sterile conditions. Small CT-
2A tumor pieces (1mm3) from a C57BL/6J donor mouse
were implanted into the right cerebral hemisphere of anaes-
thetized recipient mice as we recently described [48]. All of
the mice recovered from the surgical procedure and were
returned to their cages when fully active. Initiation of tumors
from intact tumor pieces is preferable to initiation from
cultured cells since the pieces already contain an established
microenvironment that facilitates tumor growth.
2.4. Dietary Restriction (DR). The mice were separated prior
to the beginning of the experiment and randomly assigned
to either control group that was fed AL or to an experimental
group that was fed a total dietary restriction (DR) of 30%.
Eachmousewashousedsinglyinaplasticshoeboxcagewith
a ﬁlter top and was given a cotton nesting pad for warmth.
DR was initiated 2 days following tumor implantation and
was continued for 11 days following implantation. Total
DR maintains a constant ratio of nutrients to energy; that
is, the average daily food intake (grams) for the AL fed
mice was determined every other day and the DR-fed mice
were given 70% of that quantity on a daily basis. All mice
received PROLAB chow (Agaway Inc.), which contains a
balance of mouse nutritional ingredients and, according to
the manufacturer’s speciﬁcation, delivers 4.4Kcal/g gross
energy. Body weights of all mice were recorded every other
day.
2.5. Tumor Growth and Histology. Intracerebral tumor
growth was analyzed directly by measuring total tumor wet
weight. Tumors were dissected from normal-appearing brainJournal of Oncology 3
tissue, were frozen, and then were weighed. Tumor samples
for histology were ﬁxed in 10% neutral buﬀered formalin
(Sigma) and embedded in paraﬃn. They were sectioned at
5μm, stained with haematoxylin and eosin, and examined
by light microscopy.
2.6. Measurement of Plasma Glucose and Lipids. Mice were
anesthetized with isoﬂurane (Halocarbon Laboratories,
River Edge, NJ, USA) and euthanized by exsanguination, in-
volving collection of blood from the heart in heparinized
tubes. The blood was centrifuged at 6,000g for 10min, the
plasma was collected, and aliquots were stored at −80◦C
until analysis. Plasma glucose concentration was measured
inaspectrophotometerusingtheStanbioEnzymaticGlucose
Procedure (Stanbio). High-performance thin-layer chro-
matography was used to evaluate plasma lipids according to
our standard procedures [49].
2.7. Western Blot Analysis. Frozen CT-2A tumor and con-
tralateral normal brain tissues were homogenized in lysis
buﬀer, on ice. Lysates were transferred to Eppendorf tubes,
mixed on a rocker for 1h at 4◦C, and then centrifuged
for 20min. Supernatants were collected, and protein con-
centrations were estimated using the Bio-Rad detergent-
compatible protein assay. Approximately 25μgo ft o t a l
protein from each tissue sample were denatured with SDS-
PAGE sample buﬀe ra n dr e s o l v e dw i t hS D S - P A G Eo n4 %
to 12% Bis-Tris gels (Invitrogen). Proteins were transferred
to a polyvinylidene diﬂuoride immobilon TM-P membrane
(Millipore) overnight at 4◦Ca n db l o c k e di n5 %n o n f a t
powdered milk in TBS with tween 20 (pH 7.6) for 1h at
room temperature. Membranes were probed with primary
antibodies overnight at 4◦C with gentle shaking. The blots
were then incubated with the appropriate secondary anti-
body for 1h at room temperature, and bands were visualized
with chemiluminescence. Each membrane was stripped and
reprobed for β-actin as an internal loading control, and the
ratiooftheindicatedproteintoβ-actinwasanalyzedbyscan-
ning densitometry.
2.8. Antibodies and Reagents. Antibodies were obtained
againstα-SMA (Sigma),β-Actin(Cell Signaling), FactorVIII
(Dako),PDGF-Rβ(SantaCruz),VEGF-R2(SantaCruz),and
VEGF (Santa Cruz).
2.9. Confocal Microscopy. For the immunohistochemical
studies, the tissue sections were deparaﬃnized, rehydrated,
and washed. The tissue sections were then heat treated
(95◦C) in antigen unmasking solution (Vector Laboratories,
Burlingame, CA, USA) for 30min. Tissue sections were
b l o c k e di ng o a ts e r u m( 1 : 1 0i nP B S )f o r1 ha tr o o m
temperature, treated with primary antibody, followed by
treatment with secondary antibody. Corresponding tissue
sections without primary antibody served as negative con-
trols. For confocal microscopy, digital images were obtained
on a Leica DMI6000 inverted scope equipped with the Leica
TCSSP5 confocal system, using HCX PL APO 409/1.25 NA
oil and HCX PL APO 639/1.4 NA oil objective lenses. Leica
confocal software was used to acquire images.
For α-SMA and Factor VIII immunoﬂourscent staining,
sections were incubated with a cocktail of α-SMA and Factor
VIII primary antibodies (1:100) in blocking buﬀer for
1h at room temperature, followed by a cocktail of alex-
aﬂuor 585 and 488, conjugated anti-mouse and anti-rabbit,
respectively, secondary antibody (1:200) for 45min at room
temperature.
For colocalization of VEGF-R2 and PDGF-Rβ,s e c t i o n s
were incubated with a cocktail of VEGF-R2 and PDGF-R2
primary antibodies (1:100) in blocking buﬀer overnight at
4◦C, followed by a cocktail of alexaﬂuor 585 and 488, con-
jugated anti-mouse and anti-rabbit, respectively, secondary
antibody at 1:200 dilution for 45min. All other conditions
were as stated.
2.10. Immunohistochemistry. Tissue sections were processed
similarly as for confocal microscopy. Sections were treated
with VEGF, PDGF-Rβ, and Factor VIII primary antibodies
overnight at 4◦C followed by treatment with a biotiny-
lated anti-rat secondary antibody at 1:100 dilution (Vector
laboratories, Inc). The sections were then treated with
avidin biotin complex followed by 3,3-diaminobenzidine
as substrate for staining according to the manufacturer’s
protocol (Vectastain Elite ABC kit, Vector laboratories, Inc.).
The sections were counterstained with haematoxylin and
mounted. Corresponding tissue sections without primary
antibody served as negative controls. The Zeiss Axioplan 2
light microscope was used to capture bright-ﬁeld images.
3. Results
3.1. Dietary Restriction Reduces Body Weight, Blood Glucose,
andIntracerebralTumorGrowth. TheDRgroupexhibitedan
average body weight reduction of 22 ± 1% and an average
tumor reduction of 76 ± 4%. Average tumor wet weight was
signiﬁcantly lower in the DR-fed mice (51 ± 7mg) than in
the AL-fed mice (209 ± 40mg); P<0.01, Student’s t-test.
Blood glucose levels (mmol/L) in the AL and DR mice were
8.6 ±0.6and4.4 ±1.0,respectively(P<0.05,determinedby
two-tailed t-test). The blood glucose levels were reduced in
the DR mice as we previously showed [36, 50]. No signiﬁcant
diﬀerences were detected between the AL and DR mice for
the distribution of major lipids including cholesteryl esters,
cholesterol, triglycerides, or phosphatidylcholine (data not
shown). Mouse activity level increased under dietary energy
restriction. This is a well-documented phenomenon that
occurs in all mice when placed under calorie restriction
and is due to increased foraging [51]. It is diﬃcult to
determine if increased physical activity causes psychological
stress. It is well documented that general health and ﬁtness
improves signiﬁcantly in mice when they are underfed with
adequate nutrition [51, 52]. It is important to note that
all tumors implanted grew in both the DR and AL groups,
indicating that dietary restriction did not inhibit tumor take.4 Journal of Oncology
This study conﬁrms previous observations that DR inhibits
CT-2A tumor growth [36].
3.2. Dietary Restriction Reduces Microvessel Density and
Hemorrhaging in the CT-2A Astrocytoma. H&E staining was
used to evaluate the inﬂuence of DR on hemorrhagic blood
vessels in CT-2A (Figure 1(a)). Light pink staining indicates
normal brain tissue. Bright pink staining found within the
CT-2A tumor tissue indicates hemorrhagic vasculature. The
number of hemorrhagic vessels was noticeably less in tumors
of DR-fed mice than in tumors of AL-fed mice. Factor VIII
immunohistochemistry was used to evaluate the inﬂuence of
DR on the density of vascular endothelial cells. The number
of Factor-VIII-stained endothelial cells was noticeably less in
sectionsoftumorsfromDR-fedmicethanfromAL-fedmice,
indicating a reduction of microvessel density (Figures 1(b)
and 1(c)).
3.3. Dietary Restriction Increases Maturation of Blood Vessels
in the CT-2A Astrocytoma. Confocal microscopy was used
to determine the inﬂuence of DR on localization of α-SMA
and Factor VIII in blood vessels of CT-2A (Figure 2). α-
SMA (red) was used as a marker for vascular smooth muscle
cell (VSMC)/perictye coverage of blood vessels, and Factor
VIII (green) was used as a marker for endothelial cells.
Localization of VSMCs (red) with the endothelial cell lining
(green) was greater in tumor vessels of DR-fed mice than in
tumor vessels of AL-fed mice. These ﬁndings suggest that DR
enhances VSMC/perictye coverage of CT-2A tumor vessels.
3.4. Dietary Restriction Increases α-SMA Expression and
Reduces Factor VIII Expression in the CT-2A Astrocytoma.
Western blot analysis was done to examine the eﬀects of
DR on the relative expression of α-SMA and Factor VIII in
tumor blood vessels. Factor VIII expression was signiﬁcantly
lower while α-SMA expression was signiﬁcantly higher in
the CT-2A tumor when grown in DR-fed mice than when
g r o w ni nA L - f e dm i c e( Figure 3). The ratio of α-SMA to
Factor VIII was signiﬁcantly greater in the tumors of the DR
mice as compared to the AL mice (Figure 3). An increase
of this ratio in DR mice as compared to the AL group
indicates a reduction of endothelial cell proliferation and a
simultaneous increase of pericyte/VSMC vessel coverage.
3.5. Dietary Restriction Reduces VEGF Expression in the CT-
2A Astrocytoma. Immunohistochemistry was used to de-
termine the inﬂuence of dietary restriction on local VEGF
expression in CT-2A. The brown VEGF staining intensity
and quantity was noticeably less in tumors of DR-fed mice
t h a ni nt u m o r so fA L - f e dm i c e( Figure 4). These ﬁndings are
consistent with previous ﬁndings in plasma indicating that
DR reduces VEGF expression [35, 36].
3.6. Dietary Restriction Reduces PDGF-Rβ and VEGF-R2
Association in the CT-2A Astrocytoma. Confocal microscopy
showed that the amount of yellow staining, indicative of
colocalization of PDGF-Rβ (red) and VEGF-R2 (green), was
less in DR-fed mice compared to tumors of AL-fed mice
(Figure 5(a)). Western blot analysis showed that PDGF-Rβ
expression was similar in tumors of DR-fed and AL-fed mice
(Figure 5(b)).
4. Discussion
We found for the ﬁrst time that DR could enhance tumor
blood vessel maturation in a malignant mouse astrocytoma.
DR not only curtailed angiogenesis, but also increased vessel
pericyte ensheathment in the highly vascularized CT-2A
astrocytoma. DR reduced endothelial cell proliferation, as
indicated by a reduction in staining for Factor VIII, a
marker for endothelial cells. We also observed an increase
of pericyte and vascular smooth muscle cell coverage of
the endothelial cell lining in blood vessels, as indicated by
an increase of α-SMA, a marker for VSMCs and VSMC-
like pericytes. This was apparent from the increased ratio
of α-SMA relative to Factor VIII. Our ﬁndings agree with
the previously documented antiangiogenic eﬀects of DR
[34–36, 53]. Immunostaining of tumor sections with VEGF
a n t i b o d ys h o w e da no v e r a l lr e d u c t i o no fV E G Fe x p r e s s i o ni n
DR-treated tumors. We suggest that the observed reduction
in VEGF leads to the antiangiogenic and vessel maturating
eﬀects, via the VEGF-VEGF-R2 signaling axis.
The VEGF-VEGF-R2 signaling axis is a primary pathway
in endothelial cell proliferation [54]. Moreover, Greenberg
et al. implicated VEGF in a dichotomous role. Apart from
acting as a promoter of endothelial cell function, VEGF also
acts as a negative regulator of VSMCs and consequently
vessel maturation [24]. We observed that DR reduced colo-
calization of VEGF-R2 and PDGF-Rβ in the CT-2A tumor.
We also found that DR had no signiﬁcant inﬂuence on
PDGF-Rβ expression. These ﬁndings suggest that DR blocks
the association of VEGF-R2 and PDGF-Rβ by reducing
VEGF, thus preventing inhibition of the PDGF signaling
axis due to colocolization of the two receptors [24]. Further
studies will be needed to evaluate these signaling pathways.
An immature and leaky vasculature is a hallmark of
solid tumors [55–57]. The leakiness of the tumor vasculature
leads to elevated interstitial ﬂuid pressure within the tumor.
Tong et al. demonstrated that increased hydrostatic pressure
within tumors hinders drug penetration across tumor vessels
[58]. They also showed that penetration of large molecules
into tumors is better through vessels with uniform peri-
cyte coverage than through vessels with irregular pericyte
coverage. We suggest that DR may improve drug delivery
to the tumor via a similar mechanism. Denny et al. found
that restriction of a ketogenic diet improved delivery of a
small drug molecule into the mouse brain. They found
that brain N-butyldeoxynojirmycin (NB-DNJ) content was
3.5-fold greater in the restricted ketogenic diet + NB-DNJ
mice than in the NB-DNJ group alone suggesting that DR
enhances delivery of the drug to the brain. This could allow
for a lower dosing to achieve therapeutic eﬀect [59]. Further
research on the eﬀects of dietary restriction on the brain
vasculatureisnecessarytoelucidatethemechanismbywhich
diet and DR enhance drug delivery to the brain.Journal of Oncology 5
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Figure 1: Dietary restriction reduces microvessel density and hemorrhaging in the CT-2A astrocytoma. (a) Vessel morphology. Arrows
indicate hemorrhagenic regions. (b) Microvessel density. (c) Higher magniﬁcation. Arrows indicate positive Factor VIII vessel staining. Each
stained section was representative of the entire tumor. All images were produced from digital photography.6 Journal of Oncology
Tumor AL Tumor DR Normal brain
Figure 2: Inﬂuence of dietary restriction on blood vessel maturation in the CT-2A astrocytoma. Confocal analysis of normal brain and
CT-2A tumor tissue double stained for α-SMA in vascular smooth muscle cells (red) and Factor VIII in vascular endothelial cells (green).
Results show that α-SMA is greater in the vessels of the DR-fed tumor than in the vessels of the AL-fed tumor (indicated by white arrow). A
blood vessel of a normal brain is shown for comparison. All other conditions were as described in Section 2.
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Figure 3: Dietary restriction increases α-SMA and reduces Factor VIII expression in the CT-2A astrocytoma. The histograms show the
average relative expression of the indicated protein normalized to β-actin based on Western blot analysis. Equal amounts of protein were
loaded into each lane of the Western blot (25μg). Other conditions were as described in Section 2. Values are expressed as normalized means
of three to four independent tissue samples per group ± SEM. The value is signiﬁcantly diﬀerent in the tumors of DR-fed mice than in the
tumors of AL-fed mice: ∗P<0.05, Student’s t-test. Two representative samples are shown for each tissue type.Journal of Oncology 7
AL DR
Figure 4: Dietary restriction reduces VEGF expression in the CT-2A astrocytoma. VEGF immunostained sections (400x). Results show that
VEGF expression (brown stain) is less in the tumors of DR-fed mice than in the tumors of AL-fed mice. Black arrows indicate positive VEGF
staining. Each stained section is representative of the entire tumor. All other conditions are as described in Section 2.
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Figure 5: Dietary restriction reduces PDGF-Rβ and VEGF-R2 association in the CT-2A astrocytoma. (a) Confocal analysis of CT-2A tumor
tissue double stained for VEGF-R2 (green) and PDGF-Rβ (red). Results show that the colocolization (yellow) of VEGF-R2 and PDGF-Rβ
is less in the tumors of DR-fed mice than in the tumors of AL-fed mice. White arrow indicates colocolization. All other conditions are as
described in Section 2. (b) The histogram shows that the average relative expression of PDGF-Rβ normalized to β- a c t i nb a s e do nW e s t e r n
blot analysis is similar in the tumors of DR-fed and AL-fed mice. Equal amounts of protein were loaded into each lane (25μg), and the other
conditions were as described in Section 2. Values are expressed as normalized means of three to four independent tissue samples per group
± SEM. There is no signiﬁcant diﬀerence between values of DR-fed and AL-fed mice, Student’s t-test. Two representative samples are shown
for each tissue type.8 Journal of Oncology
It is well documented that prognosis is poor for most
patients with malignant glioma [60]. The targeting of an-
giogenesis has become an important strategy in current
therapy [61, 62]. The goal of antiangiogenic therapy is to
reducemicrovesseldensityandtoincreasevesselstabilization
[9,60–62].WesuggestthatDRnormalizestumorvasculature
by decreasing VEGF expression in the tumor. Our ﬁndings
show that mature smooth-muscle-cell-covered vessels are
more prominent in brain tumors under DR than in brain
tumors under AL feeding.
5. Conclusions
The results indicate that dietary restriction promotes vessel
maturationinanexperimentalmouseastrocytoma.Thispre-
clinical study shows that DR may be an eﬀective nontoxic
antiangiogenic therapy in brain tumors. DR may also im-
prove drug delivery to brain tumors and may therefore be
used in conjunction with drug therapy.
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